Home > Insider Trading > Filing (0001073397-21-000002)

Filing Details

Accession Number:: 0001073397-21-000002
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-04-12 18:24:06
Reporting Period:: 2021-04-08

Accepted Time:: 2021-04-12 18:24:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
883984	Icu Medical Inc	ICUI	Surgical & Medical Instruments & Apparatus (3841)	330022692

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1073397	A George Lopez	951 Calle Amanecer San Clemente CA 92673		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-04-08	5,914	$203.22	955,929	No	4	S	Indirect	by Partnership
Common Stock	Disposition	2021-04-08	2,868	$204.00	953,061	No	4	S	Indirect	by Partnership
Common Stock	Disposition	2021-04-08	1,118	$204.99	951,943	No	4	S	Indirect	by Partnership
Common Stock	Disposition	2021-04-09	4,650	$203.11	947,293	No	4	S	Indirect	by Partnership
Common Stock	Disposition	2021-04-09	5,350	$203.84	941,943	No	4	S	Indirect	by Partnership
Common Stock	Disposition	2021-04-09	400	$204.70	941,543	No	4	S	Indirect	by Partnership
Common Stock	Disposition	2021-04-12	167	$205.23	941,376	No	4	S	Indirect	by Partnership
Common Stock	Disposition	2021-04-12	4,149	$206.10	937,227	No	4	S	Indirect	by Partnership
Common Stock	Disposition	2021-04-12	384	$206.78	936,843	No	4	S	Indirect	by Partnership

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	by Partnership
No	4	S	Indirect	by Partnership
No	4	S	Indirect	by Partnership
No	4	S	Indirect	by Partnership
No	4	S	Indirect	by Partnership
No	4	S	Indirect	by Partnership
No	4	S	Indirect	by Partnership
No	4	S	Indirect	by Partnership
No	4	S	Indirect	by Partnership

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	240,314	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.69 to $203.63, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.68 to $204.53, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.73 to $205.55, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.52 to $203.51, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.52 to $204.23, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.55 to $204.82, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.43 to $205.34, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.47 to $206.45, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.48 to $207.03, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.